Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study

by Moreno C., Berg T., Tanwandee T., Thongsawat S., Van Vlierberghe H., Zeuzem S., Lenz O., Peeters M., Sekar V., De Smedt G.
Published 2017

Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naïve individuals in Cambodia, Thailand and Vietnam: An ANRS AC12 working group study

by Nouhin J., Donchai T., Hoang K.T.H., Ken S., Kamkorn J., Tran T., Ayouba A., Peeters M., Chaix M.-L., Lien T.X., Nerrienet E., Ngo-Giang-Huong Nicole N.
Published 2014

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: Programmatic implications for countries phas...

by Tang M.W., Rhee S.-Y., Bertagnolio S., Ford N., Holmes S., Sigaloff K.C., Hamers R.L., De Wit T.F.R., Fleury H.J., Kanki P.J., Ruxrungtham K., Hawkins C.A., Wallis C.L., Stevens W., Van Zyl G.U., Manosuthi W., Hosseinipour M.C., Ngo-Giang-Huong N., Belec L., Peeters M., Aghokeng A., Bunupuradah T., Burda S., Cane P., Cappelli G., Charpentier C., Dagnra A.Y., Deshpande A.K., El-Katib Z., Eshleman S.H., Fokam J., Gody J.-C., Katzenstein D., Koyalta D.D., Kumwenda J.J., Lallemant M., Lynen L., Marconi V.C., Margot N.A., Moussa S., Ndung'U T., Nyambi P.N., Orrell C., Schapiro J.M., Schuurman R., Sirivichayakul S., Smith D., Zolfo M., Jordan M.R., Shafer R.W.
Published 2014